An official website of the United States government
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
Trial Status: complete
This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an
oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells
of the immune system. This trial will study the safety, tolerability, and anti-tumor
activity of ciforadenant as a single agent and in combination with atezolizumab, a PD-L1
inhibitor against various solid tumors. Ciforadenant blocks adenosine from binding to the
A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune
cells.
Inclusion Criteria
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.
Documented pathologic diagnosis of clear cell RCC.
Relapsed or refractory to 1-2 prior lines of therapy containing at least an anti-PD-(L)1 agent.
History of severe hypersensitivity reaction to monoclonal antibodies.
Has immunodeficiency or requires treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment or anticipation of need for systemic immunosuppressant medication during study treatment.
Has an active autoimmune disease requiring systemic treatment with in the past 2 years OR a documented history of clinically severe autoimmune disease. Metastatic Castration-Resistant Prostate Cancer
Additional locations may be listed on ClinicalTrials.gov for NCT02655822.
